Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bIAP versus placebo for prevention of post-surgical inflammatory response after combined aortic valve replacement and CABG
NL-OMON38040Phase 3Active, not recruiting
- Sponsor
- Alloksys Life Sciences
- Start
- Apr 2010
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Systemic Inflammatory Response Syndrome (SIRS) comparing bIAP with Placebo (2 arms). Primary endpoints: Reduction of post-surgical inflammatory response, Fulminant SIRS response by pro-inflammatory cytokines and 1 more. Started Apr 2010; status: active, not recruiting.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NL-OMON38040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38040.